TD Securities analyst Daniel Chan initiates coverage on Thinkific Labs (OTC:THNCF) with a Hold rating and announces Price Target of $2.75.
FDA Approves Gilead’s Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment
The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment,
